Streetbeat News

Analyst Ratings

AXSM

RBC Capital has maintained its 'Outperform' rating on Axsome Therapeutics and slightly raised the price target from $130 to $131.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:08 pm

TELA

TELA Bio (NASDAQ:TELA) has been the subject of recent analyst reviews, with 6 analysts providing ratings ranging from bullish to bearish. The average 12-month price target has decreased by 16.48% to $11.0. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. TELA Bio, a medical technology company, has shown revenue growth but faces challenges with profitability, debt management, and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

EE

Analysts have mixed ratings for Excelerate Energy (NYSE:EE), with recent price targets averaging $21.2, reflecting a slight increase. The company's financial performance shows challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

NBIX

Neurocrine Biosciences (NASDAQ:NBIX) has received diverse analyst ratings over the past three months, with a mix of bullish and bearish outlooks. Analysts have set a 12-month average price target of $166.7, reflecting a 2.93% increase from the previous target. The company's financial performance is strong, with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has been evaluated by 13 analysts, showing a mix of bullish and bearish perspectives. The average 12-month price target is $17.38, a 21.53% decrease from the previous target. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Sage Therapeutics is a clinical-stage biopharmaceutical company focusing on brain health medicines, with significant revenue growth but challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

HROW

Lake Street analyst Brooks O'Neil has maintained a Buy rating on Harrow (NASDAQ:HROW) and raised the price target from $45 to $55.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:00 pm

GPN

Analysts have provided mixed ratings for Global Payments (NYSE:GPN) over the past three months, with a decrease in the average 12-month price target from $147.72 to $140.33. Recent actions by analysts include several downgrades in price targets, reflecting a cautious outlook. Despite positive revenue growth, Global Payments faces challenges in profitability and financial performance compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

CBRE

Analysts have varied ratings for CBRE Group, ranging from bullish to bearish. Recent analyst actions show raised price targets and ratings, indicating positive sentiment. CBRE's financials reveal strong market position, revenue growth, and profitability, with efficient debt management.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

LIVN

LivaNova Plc (NASDAQ:LIVN) is expected to see revenue and profit gains due to new product cycles and strategic shifts, according to Goldman Sachs analyst David Roman. He initiated coverage with a Buy rating and a $65 price target, citing potential 5% revenue growth and 14% EPS growth through 2027.

Portfolio Pulse from Priya Nigam

October 04, 2024 | 3:59 pm

VRCA

RBC Capital analyst Gregory Renza maintains an Outperform rating on Verrica Pharmaceuticals but lowers the price target from $13 to $11.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:56 pm